For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
3
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
phase
3
BIMZELX® (bimekizumab-bkzx)
Plaque Psoriasis
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the Be Bright open-label extension trial
phase
2
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
phase
3
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
phase
4/RWE
Generalized Myasthenia Gravis
Risk of exacerbation and level of healthcare resource utilization in myasthenia
phase
3
ZILBRYSQ® (zilucoplan)
Generalized Myasthenia Gravis
Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Rozanolixizumab improved symptoms in people with generalised myasthenia gravis in the MycarinG clinical study: a Plain Language Summary of Publication
phase
3
BIMZELX® (bimekizumab-bkzx)
Hidradenitis Suppurativa
Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open‑label extension MG0004 study